Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

被引：13
作者：
Brazel, Danielle [1 ]
Ou, Sai-Hong Ignatius [1 ,2 ]
Nagasaka, Misako [1 ,2 ,3 ,4 ]
机构：
[1] Univ Calif Irvine Sch Med, Dept Med, Orange, CA USA
[2] Chao Family Comprehens Canc Ctr, Orange, CA USA
[3] St Marianna Univ Sch Med, Kawasaki, Japan
[4] Univ Calif Irvine Sch Med, Dept Med, 101 City Dr, Orange, CA 92617 USA
来源：
LUNG CANCER-TARGETS AND THERAPY | 2023年 / 14卷
关键词：
tiragolumab; TIGIT; immunotherapy; small cell lung cancer; CELL LUNG-CANCER; PVR;
D O I：
10.2147/LCTT.S379389
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III SKYSCRAPER-02 failed to find PFS or OS benefit in patients with SCLC. Atezolizumab was the first immunotherapy to show survival benefit in extensive SCLC based on the phase III IMpower133 study. Given that immunotherapy has become the standard of care for SCLC patients, further research is needed into ways to augment the immune system to better treat these patients.
引用
收藏
页码：1 / 9
页数：9
相关论文
共 30 条
  • [1] [Anonymous], 2022, Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
  • [2] [Anonymous], 2022, GENENTECH PROVIDES U
  • [3] Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
    Bendell, Johanna C.
    Bedard, Philippe
    Bang, Yung-Jue
    LoRusso, Patricia
    Hodi, Stephen
    Gordon, Michael
    D'Angelo, Sandra
    Desai, Jayesh
    Garralda, Elena
    Italiano, Antoine
    Myung-Ju Ahn
    Cervantes, Andres
    Wainberg, Zev
    Calvo, Emiliano
    Gil-Martin, Marta
    Martinez-Garcia, Maria
    Bahleda, Rastilav
    Cassier, Philippe
    Delord, Jean-Pierre
    Prawira, Amy
    Melero, Ignacio
    Emens, Leisha
    Romano, Emanuela
    Miller, Karen
    Hsieh, Robert W.
    Xue, Cloris
    Morrissey, Kari
    Twomey, Patrick
    Gash, Kelly
    Patil, Namrata S.
    Grogan, Jane
    Meng, Raymond
    Cho, Byoung
    Kim, Tae Won
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [4] A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
    Boles, Kent S.
    Vermi, William
    Facchetti, Fabio
    Fuchs, Anja
    Wilson, Timothy J.
    Diacovo, Thomas G.
    Cella, Marina
    Colonna, Marco
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (03) : 695 - 703
  • [5] Targeting PVR (CD155) and its receptors in anti-tumor therapy
    Brlic, Paola Kucan
    Rovis, Tihana Lenac
    Cinamon, Guy
    Tsukerman, Pini
    Mandelboim, Ofer
    Jonjic, Stipan
    [J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2019, 16 (01) : 40 - 52
  • [6] Caruso C, 2020, CANCER DISCOV, V10, P1086, DOI 10.1158/2159-8290.CD-NB2020-063
  • [7] Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
    Cho, Byoung Chul
    Abreu, Delvys Rodriguez
    Hussein, Maen
    Cobo, Manuel
    Patel, Anjan J.
    Secen, Nevena
    Lee, Ki Hyeong
    Massuti, Bartomeu
    Hiret, Sandrine
    Yang, James Chih Hsin
    Barlesi, Fabrice
    Lee, Dae Ho
    Ares, Luis Paz
    Hsieh, Robert W.
    Patil, Namrata S.
    Twomey, Patrick
    Yang, Xiaoying
    Meng, Raymond
    Johnson, Melissa L.
    [J]. LANCET ONCOLOGY, 2022, 23 (06) : 781 - 792
  • [8] Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
    Gay, Carl M.
    Stewart, C. Allison
    Park, Elizabeth M.
    Diao, Lixia
    Groves, Sarah M.
    Heeke, Simon
    Nabet, Barzin Y.
    Fujimoto, Junya
    Solis, Luisa M.
    Lu, Wei
    Xi, Yuanxin
    Cardnell, Robert J.
    Wang, Qi
    Fabbri, Giulia
    Cargill, Kasey R.
    Vokes, Natalie, I
    Ramkumar, Kavya
    Zhang, Bingnan
    Della Corte, Carminia M.
    Robson, Paul
    Swisher, Stephen G.
    Roth, Jack A.
    Glisson, Bonnie S.
    Shames, David S.
    Wistuba, Ignacio I.
    Wang, Jing
    Quaranta, Vito
    Minna, John
    Heymach, John, V
    Byers, Lauren Averett
    [J]. CANCER CELL, 2021, 39 (03) : 346 - +
  • [9] Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
    Goldman, Jonathan W.
    Dvorkin, Mikhail
    Chen, Yuanbin
    Reinmuth, Niels
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian J.
    Ozguroglu, Mustafa
    Ji, Jun Ho
    Garassino, Marina Chiara
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Ponce, Santiago
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Kazarnowicz, Andrzej
    Losonczy, Gyorgy
    Conev, Nikolay V.
    Armstrong, Jon
    Byrne, Natalie
    Thiyagarajah, Piruntha
    Jiang, Haiyi
    Paz-Ares, Luis
    [J]. LANCET ONCOLOGY, 2021, 22 (01) : 51 - 65
  • [10] Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
    Govindan, Ramaswamy
    Page, Nathan
    Morgensztern, Daniel
    Read, William
    Tierney, Ryan
    Vlahiotis, Anna
    Spitznagel, Edward L.
    Piccirillo, Jay
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) : 4539 - 4544
123